Singapore, Aug. 14 -- Singapore-based biotech startup K2 Therapeutics has announced the appointment of Dr Ying Huang as Chief Executive Officer (CEO). K2 was founded with $50 million in seed financing from MPM BioImpact.

Founded by MPM BioImpact in 2024, K2 is advancing a new model for biotechnology innovation, combining worldwide asset sourcing and experienced drug development leadership to identify and advance high-potential first-in-class and best-in-class therapeutic candidates. The seed financing has supported the expansion of the Company's portfolio and advancement of its globally sourced assets.

Dr Huang brings more than two decades of experience spanning biotechnology research and development, corporate strategy, capital markets...